UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | F | G | H | J | L | M | O | P | R | S | T | V | W
Number of items: 45.

A

Alonso, S; Izagirre, N; L&oacute;pez, S; Smith-Zubiaga, I; Hervella, M; Boyano, MD; Arroyo-Berdugo, Y; ... de la R&uacute;a, C; + view all (2010) The Diversity Profile of <i>TP53</i> Is Influenced by Positive Selection on the Immediately Upstream Locus<i> WDR79</i>. Human Heredity , 69 (1) pp. 34-44. 10.1159/000243152.

Arkenau, H; (2010) Principles of Anticancer Drug Development. In: Garrett-Mayer, E, (ed.) Principles of Anticancer Drug Development. Springer Verlag

B

Benson, C; Kristeleit, RS; Ashley, S; Dolly, S; Mikropoulos, C; O'Brien, M; Popat, S; (2010) Retrospective review of all patients with thymoma treated over the last 33 years at the Royal Marsden Hospital. Journal of Clinical Oncology , 28 (15)

Bockenhauer, D; Reichold, M; Zdebik, A; Lieberer, E; Schmidt, K; Rapedius, M; Bandulik, S; ... Kleta, R; + view all (2010) Altered Renal Tubular Ultrastructure and Electrophysiology Caused by KCNJ10 Mutations in EAST Syndrome. PEDIATR NEPHROL , 25 (9) 1980 - 1980.

Bridgewater J, ; Pereira, SP; (2010) Cancers of the gastrointestinal tract. In: Warrell, DA and Cox, TM and Firth, JD and Benz, EJ, (eds.) Oxford Textbook of Medicine. Oxford University Press: Abingdon, UK.

Brunetto, AT; Kristeleit, RS; de Bono, JS; (2010) Early oncology clinical trial design in the era of molecular-targeted agents. Future Oncol , 6 (8) pp. 1339-1352. 10.2217/fon.10.92.

Bublil, EM; Pines, G; Patel, G; Fruhwirth, G; Ng, T; Yarden, Y; (2010) Kinase-mediated quasi-dimers of EGFR. The FASEB Journal , 24 (12) pp. 4744-4755. 10.1096/fj.10-166199.

C

Calvert, AH; (2010) PARP INHIBITORS IN CLINICAL DEVELOPMENT - AN OVERVIEW. In: ANNALS OF ONCOLOGY. (pp. 17 - 17). OXFORD UNIV PRESS

Cox, ST; Stephens, HA; Fernando, R; Harber, M; Howie, A; Powis, S; Zou, Y; ... Little, A-M; + view all (2010) MICA allele mismatching, MICA antibodies and rejection in renal transplantation. In: (Proceedings) 24th European Immunogenetics and Histocompatibility Conference/17th Annual Meeting of the Italian-Society-for-Immunogenetics-and-Transplantation-Biology. (pp. p. 481). WILEY-BLACKWELL PUBLISHING, INC

F

Fish, R; Pinney, J; Jain, P; Addison, C; Jones, C; Jayawardene, S; Booth, J; ... Hutchison, CA; + view all (2010) The Incidence of Major Hemorrhagic Complications After Renal Biopsies in Patients with Monoclonal Gammopathies. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY , 5 (11) pp. 1977-1980. 10.2215/CJN.00650110.

Ford, H; Hochhauser, D; Paterson, A; Lovat, L; Jobanputra, M; Fitzgerald, RC; (2010) Phase Ib trial of lapatinib oxaliplatin and capecitabine in early HER2-overexpressing esophagogastric cancer. JOURNAL OF CLINICAL ONCOLOGY , 28 (15) 10.1200/jco.2010.28.15_suppl.tps339.

Forster, MD; Patnaik, A; Sandhu, SK; Papadopoulos, K; Tromp, BJ; Messiou, C; Balkwill, F; ... Tolcher, AW; + view all (2010) Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors. In: AMER SOC CLINICAL ONCOLOGY

Forster, MD; Saijo, N; Seymour, L; Calvert, H; (2010) Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan. CLIN CANCER RES , 16 (6) 1737 - 1744. 10.1158/1078-0432.CCR-09-2228.

G

Gunaratnam, M; Neidle, S; (2010) An evaluation cascade for G-quadruplex telomere targeting agents in human cancer cells. In: UNSPECIFIED (pp. 303-313).

H

Han, L; Kristeleit, RS; van Hagen, T; Yap, T; Olmos, D; Carden, C; Kaye, S; (2010) Characterizing the experience of gynecologic oncology patients in phase 1 studies. Gynecologic Oncology , 116 (3) pp. 59-60.

Howie, AJ; Owen-Casey, MP; (2010) Discrepancies between descriptions and illustrations of colours in Congo red-stained amyloid, and explanation of discrepant colours. Amyloid , 17 (3-4) pp. 109-117. 10.3109/13506129.2010.527448.

J

jones, A; lechner, M; fourkala, E; Kristeleit, R; Widschwendter, M; (2010) Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. Epigenomics , 2 (1) pp. 9-38.

L

Lee, SM; (2010) First-line maintenance (1LM) treatment: a new strategy to treat advanced NSCLC. Oncology News , 4 (6) pp. 88-91.

M

Mahendran, AO; Papakrivopolou, J; Haroon, S; Dupont, PJ; Howie, AJ; Veitch, PS; (2010) The Troubled Transplant: Can Early Surveillance Biopsy Predict the "At Risk Graft?". In: (Proceedings) 10th American Transplant Congress. (pp. pp. 437-438). WILEY-BLACKWELL PUBLISHING, INC

Marsh, D; Suchak, K; Moutasim, KA; Vallath, S; Hopper, C; Jerjes, W; Upile, T; ... Thomas, GJ; + view all (2010) Stromal features are predictive of disease mortality in oral cancer patients. J Pathol 10.1002/path.2830.

Meyer, T; Roughton, M; Yu, D; Davies, N; Williams, E; Pereira, S; Hochhauser, D; ... Burroughs, AK; + view all (2010) A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC). In: (Proceedings) ASCO Annual Meeting. (pp. 4025-).

Molife, LR; Forster, MD; Krebs, M; Pwint, T; Middleton, MR; Kaye, SB; McCormack, P; ... Ranson, M; + view all (2010) A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors. In: AMER SOC CLINICAL ONCOLOGY

Munding, J; Baraniskin, A; Meier, D; Porschen, R; Arkenau, H; Graeven, U; Schulmann, K; ... Reinacher-Schick, A; + view all (2010) Value of SMAD4 in patients with advanced colorectal cancer (aCRC) receiving an oxaliplatin containing first line chemotherapy - a study of the AIO colorectal cancer group (AIO). ONKOLOGIE , 33 71 - 72.

O

Oliveira, JP; Fogo, AB; Bostad, L; Svarstad, E; Cook, WJ; Moll, S; Barbey, F; ... Warnock, DG; + view all (2010) SCORING SYSTEM FOR RENAL PATHOLOGY IN FABRY DISEASE: REPORT OF THE INTERNATIONAL STUDY GROUP OF FABRY NEPHROPATHY (ISGFN). In: (Proceedings) 10th Annual European Round Table on Fabry Disease. (pp. S105-S105). ELSEVIER

P

PEDLEY, R; Sharma, SK; (2010) Xenograft Mouse Models for Tumour Targeting. In: Kontermann, R, (ed.) Antibody Engineering. Springer Verlag

Patkar, V; Acosta, D; Fox, J; Jones, A; Davidson, T; Keshtgar, M; (2010) A novel support tool for Breast Multidisciplinary Meetings: an advanced evidence based computer decision support technology. In: EJC SUPPLEMENTS. (pp. 211 - 211). PERGAMON-ELSEVIER SCIENCE LTD

Patkar, V; Acosta, D; Naughton, P; Fox, J; Jones, A; Keshtgar, M; (2010) An advanced computerised decision support system for breast cancer multidisciplinary meetings: results of an audit study. In: BRITISH JOURNAL OF SURGERY. (pp. 42 - 42). JOHN WILEY & SONS LTD

Pearce, S; Gibson, F; Fern, L; O'Hare, C; Taylor, R; Whelan, JS; (2010) The 'Essence of care study' for teenagers and young adults with cancer: a national longitudinal study to assess the benefits of specialist care. Phase I: feasibility and scoping study.

R

Radhakrishnan, S; Miranda, E; Ekblad, M; Holford, A; Pizarro, MT; Lemoine, NR; Halldén, G; (2010) Efficacy of Oncolytic Mutants Targeting pRb and p53 Pathways Is Synergistically Enhanced When Combined with Cytotoxic Drugs in Prostate Cancer Cells and Tumor Xenografts. Human Gene Therapy , 21 (10) pp. 1311-1325. 10.1089/hum.2010.019.

Ringland, CL; Arkenau, H-T; O'Connell, DL; Ward, RL; (2010) Second primary colorectal cancers (SPCRCs): experiences from a large Australian Cancer Registry. ANNALS OF ONCOLOGY , 21 (1) pp. 92-97. 10.1093/annonc/mdp288.

S

Shamash, J; Stebbing, J; Sweeney, C; Sonpavde, G; Harland, S; Dawkins, G; Brock, C; ... Powles, T; + view all (2010) A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer , 116 (15) pp. 3595-3602. 10.1002/cncr.25194.

T

Theodoraki, A; Khoo, B; Hamda, A; Grillo, F; Meyer, T; Bouloux, PM; (2010) Malignant somatostatinoma presenting with diabetic ketoacidosis and inhibitory syndrome: pathophysiologic considerations. Endocr.Pract. pp. 1-12. 10.4158/EP10109.CR.

Theodoraki, A; Khoo, B; Hamda, A; Meyer, T; Bouloux, PM; (2010) Malignant Somatostatinoma Presenting with Diabetic Ketoacidosis. In: ENDOCRINE REVIEWS. (pp. ? - ?). ENDOCRINE SOC

Tobias, J; Hochhauser, D; (2010) Cancer and Its Management. [Book]. Wiley-Blackwell

Tolner, B; Vigor, K; Mather, S; Robinson, M; Adams, G; Plueckthun, A; Chester, K; (2010) Anti-HER2 imaging agents for breast cancer imaging. In: BREAST CANCER RESEARCH. (pp. S13 - S13). BIOMED CENTRAL LTD

Toumpanakis, C; Caplin, M; Quigley, A; Marelli, L; Chilkunda, D; Khan, M; Meyer, T; (2010) 90 YTTRIUM-DOTA-OCTREOTATE FOR THE TREATMENT OF ADVANCED NEUROENDOCRINE TUMOURS. In: (Proceedings) 12th World Congress on Gastrointestinal Cancer. (pp. pp. 13-14). OXFORD UNIV PRESS

V

Vanhaesebroeck, B; Vogt, PK; Rommel, C; (2010) PI3K: From the bench to the clinic and back. Current Topics in Microbiology and Immunology , 347 (1) 1 - 19. 10.1007/82-2010-65.

Vassileva, V; Piquette-Miller, M; (2010) Inflammation: Extinguishing the Fires Within. CLINICAL PHARMACOLOGY & THERAPEUTICS , 87 (4) pp. 375-379. 10.1038/clpt.2010.10.

von Minckwitz, G; Schwedler, K; Schmidt, M; Barinoff, J; Mundhenke, C; Cufer, T; Maartense, E; ... Loibl, S; + view all (2010) Abstract P6-14-05: Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment. In: (pp. P6-14-05-P6-14-05).

W

Walker, RJE; Toumpanakis, C; Marelli, L; Yu, D; Davies, N; Woodward, N; Goode, A; ... Caplin, ME; + view all (2010) Transarterial embolization/chemoebolization for hepatic NET metastases: recent efficacy and toxicity data. In: (Proceedings) 18th International Symposium on Regulatory Peptides. (pp. p. 6). ELSEVIER SCIENCE BV

Whelan, JS; Casali, P; Blay, JS; (2010) Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Ann Oncol , Suppl pp. 198-203.

Whelan, JS; Casali, PG; Blay, JY; (2010) Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Ann Oncol , Suppl pp. 98-102.

Whelan, JS; Grimer, R; Athansou, N; Gerrand, C; Judson, I; Lewis, I; Morland, B; ... Seddon, B; + view all (2010) UK guidelines for the management of bone sarcomas. Sarcoma 2010:317462. Epub

Whelan, JS; Ladenstein, R; Potschger, U; Le Deley, M-C; Paulussen, M; Oberlin, O; van der Berg, H; ... Jurgens, H; + view all (2010) Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial. J Clin Oncol , 10 (28) pp. 3284-3291.

Woodbine, L; Grigoriadou, S; Goodarzi, AA; Riballo, E; Tape, C; Oliver, AW; van Zelm, MC; ... Jeggo, PA; + view all (2010) An Artemis polymorphic variant reduces Artemis activity and confers cellular radiosensitivity. DNA REPAIR , 9 (9) pp. 1003-1010. 10.1016/j.dnarep.2010.07.001.

This list was generated on Sun May 27 01:57:00 2018 BST.